Entry of coronavirus like SARS-CoV and SARS-CoV-2 into host cells is mediated by the binding of the viral trimeric transmembrane spike (S) glycoprotein with human angiotensin-converting enzyme 2 (ACE2) on the host cell surface. The spike protein is the major target of neutralizing antibodies, and it is the focus of therapeutic drug and vaccine development.
To create a suitable model of simulating SARS-CoV-2 entry, a pseudotyped lentiviral vector is constructed with the envelope glycoprotein replaced by SARS-CoV-2 S protein. This model is able to accelerate the discovery of neutralizers like antibodies that disrupt the entry of virus into cells by blocking the binding of the S protein with ACE2 protein. With a reporter gene engineered in the pseudovirus, the neutralizing activity can be assessed with a great sensitivity and stability.
Pseudovirus neutralization assay
Live virus neutralization assay
Figure 1. Comparable IC50 values of live virus and pseudovirus neutralization assay using the same sample.
Neutralization by ACE2-Fc
Figure 2. Positive control ACE2-Fc can effectively inhibit pseudovirus entry in a dose-dependent manner
Consistent IC50 in independent tests
Figure 3. Antibody candidates were screened for their ability to inhibit pseudovirus entry.
Neutralization by immunized mice serum
Figure 4. Immunized mouse serum can effectively inhibit pseudovirus entry
Delivery: Neutralization assay report
QC standard: S/N ≥ 100
Turnaround time: 1-3 weeks*
*TAT may extend due to the number of samples.
Available cell line for blocking and neutralization assays
* Components can be purchased separately.
Please contact GenScript ProBio for details.